Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9% - Time to Buy?

Key Points

• Phase‑2 DAZALS data87% lower death risk in ALS, which is the main near‑term clinical catalyst driving recent buying interest.
• Q1 results were mixed: revenue of $164.9M missed consensus (~$185.8M) and GAAP EPS swung to a -$0.30 loss, but management raised its 2026 sales outlook citing growth from Lifyorli and other initiatives.
• Shares jumped 7.9% intraday to about $50.19; analysts maintain a "Moderate Buy" consensus with an average target of ~$72, and insider activity included a director buying 100,000 shares while the CEO sold ~26,198 shares.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report)'s share price was up 7.9% during mid-day trading on Friday . The company traded as high as $50.04 and last traded at $50.1850. Approximately 1,308,269 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 1,893,790 shares. The stock had previously closed at $46.52.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase‑2 DAZALS data showed a large survival benefit in ALS (reported as an ~87% lower death risk), a potential material clinical and valuation catalyst if confirmed in later trials; this is the main near‑term driver of buying interest. Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
• Positive Sentiment: Management raised its 2026 sales outlook, citing growth driven by Lifyorli and other commercial initiatives — a constructive sign that the company sees stronger revenue later in the year. CORT Q1 earnings match estimates, revenues miss, 2026 outlook raised
• Neutral Sentiment: Company reported Q1 revenue of $164.9M (up ~4.9% year‑over‑year) and provided a corporate update; revenue growth exists but is modest. Corcept Therapeutics Announces First-Quarter Financial Results and Provides Corporate Update
• Neutral Sentiment: Management commentary and the full earnings‑call transcript provide context on commercialization plans and the DAZALS program; investors will watch upcoming milestones and regulatory plans. Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 revenue missed Street expectations (consensus ~ $185.8M vs $164.9M reported), a shortfall that tempers the quarter’s headline and likely pressured some sellers. Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: GAAP EPS swung to a loss (-$0.30) versus $0.17 a year ago and missed some analyst models, highlighting near‑term profitability pressure despite longer‑term upside from clinical programs. Corcept: Q1 Earnings Snapshot

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Canaccord Genuity Group lifted their target price on Corcept Therapeutics from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, March 26th. HC Wainwright cut their target price on Corcept Therapeutics from $67.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday, March 25th. Wolfe Research raised shares of Corcept Therapeutics from an "underperform" rating to a "peer perform" rating in a research note on Thursday, March 26th. Piper Sandler upped their target price on Corcept Therapeutics from $73.00 to $88.00 and gave the company an "overweight" rating in a report on Friday. Finally, Zacks Research cut shares of Corcept Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $72.17.

Corcept Therapeutics Price Performance

The company has a market capitalization of $5.51 billion, a P/E ratio of 62.96 and a beta of 0.25. The company's 50-day simple moving average is $39.14 and its 200 day simple moving average is $54.61. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The company had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. Corcept Therapeutics's quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the business earned $0.17 earnings per share. As a group, sell-side analysts expect that Corcept Therapeutics Incorporated will post 0.23 earnings per share for the current fiscal year.

Insider Buying and Selling at Corcept Therapeutics

In other news, Director G Leonard Baker, Jr. purchased 100,000 shares of the company's stock in a transaction dated Tuesday, March 17th. The shares were bought at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the transaction, the director directly owned 1,146,631 shares in the company, valued at $37,999,351.34. This trade represents a 9.55% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 26,198 shares of the company's stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the sale, the chief executive officer directly owned 2,918,326 shares of the company's stock, valued at approximately $146,120,582.82. This represents a 0.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 86,198 shares of company stock worth $3,668,569 over the last 90 days. Insiders own 20.80% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC acquired a new stake in shares of Corcept Therapeutics in the first quarter worth $265,000. Whittier Trust Co. grew its position in Corcept Therapeutics by 1,243.8% in the 1st quarter. Whittier Trust Co. now owns 5,402 shares of the biotechnology company's stock worth $221,000 after purchasing an additional 5,000 shares during the last quarter. Simplify Asset Management Inc. bought a new position in shares of Corcept Therapeutics during the 1st quarter worth about $1,522,000. Patten Group Inc. acquired a new position in shares of Corcept Therapeutics during the first quarter valued at about $519,000. Finally, Formidable Asset Management LLC lifted its stake in shares of Corcept Therapeutics by 87.5% in the first quarter. Formidable Asset Management LLC now owns 11,681 shares of the biotechnology company's stock valued at $471,000 after buying an additional 5,450 shares during the period. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.